Colon Cancer News and Research

Latest Colon Cancer News and Research

Asbestos induces cell necrosis, promotes tumor growth

More than 20 million people in the U.S., and many more worldwide, who have been exposed to asbestos are at risk of developing mesothelioma, a malignant cancer of the membranes that cover the lungs and abdomen that is resistant to current therapies.

30 Jun 2010

Tolerx presents preclinical data on TRX518 anti-GITR immunotherapy for cancer

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, presented results from preclinical studies with TRX518, an early-stage agent Tolerx is developing as a treatment for cancer. TRX518 is a monoclonal antibody to glucocorticoid-induced tumor necrosis factor receptor (GITR) and is designed to enhance the immune system's ability to attack tumors by activating and rendering T effector cells resistant to T regulatory cell suppression.

28 Jun 2010

Automated calls can increase colon cancer screening rates by 30%: Study

Simple, automated telephone reminders can increase colon cancer screening rates by 30 percent, according to a Kaiser Permanente Center for Health Research study funded by the National Cancer Institute that appears in the July print edition of Medical Care.

25 Jun 2010

Scientists report potential toxicity of nanoparticles in consumer products

Scientists are reporting that particle size affects the toxicity of zinc oxide, a material widely used in sunscreens. Particles smaller than 100 nanometers are slightly more toxic to colon cells than conventional zinc oxide. Solid zinc oxide was more toxic than equivalent amounts of soluble zinc, and direct particle to cell contact was required to cause cell death.

25 Jun 2010

Shift in balance between good and bad bacteria in gut could be a harbinger of colon cancer: Study

The human body contains more bacteria than it does cells. These bacterial communities can have a positive effect on our health, by training our immune systems and helping to metabolize the foods we eat. But they can also set us up to develop digestive disorders, skin diseases, and obesity.

23 Jun 2010

New presentations on neuroendocrine tumors at ESMO 12th World Congress on Gastrointestinal Cancer

Groundbreaking studies will be presented at the ESMO 12th World Congress on Gastrointestinal Cancer next week in Barcelona, Spain, including exciting new data on treatment for neuroendocrine tumors. "The presentations this year are very significant for clinicians, and outline real progress in the development of agents that are effective in managing and treating gastrointestinal diseases," says Eric Van Cutsem, MD, PhD of the University Hospital Gasthuisberg in Leuven, Belgium and Congress co-chair.

23 Jun 2010

Protect Your Lungs, LUNGevity Foundation announce merger

To combat the nation's number one cancer killer, non-profit organizations Protect Your Lungs and LUNGevity Foundation today announced they will join forces in an effort to fund research and hope for a cure for lung cancer. Together, the new organization hopes to create the same successful improvements for lung cancer mortality rates as those experienced by breast, prostate, and colon cancer. The merged organization, committed to elevating lung cancer on the national agenda, will operate under the name LUNGevity Foundation with offices in Washington, D.C. and Chicago.

18 Jun 2010

Curis reports topline results from GDC-0449 Phase II clinical trial for metastatic colorectal cancer

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced topline results from a Phase II clinical trial conducted by Roche and Genentech, Curis' collaborator and a wholly owned member of the Roche Group, of GDC-0449, a first-in-class Hedgehog pathway inhibitor. GDC-0449 was tested in combination with Avastin® (bevacizumab) and FOLFOX or FOLFIRI chemotherapy in first-line metastatic colorectal cancer patients.

17 Jun 2010

Researchers examine rates of cancer in British white and British Indian population

British Indians have fewer cases of many different cancers including breast, prostate, colon and lung than the British white population, according to new research published in the British Journal of Cancer1 today (Wednesday).

16 Jun 2010

CRH Medical's marketing program provides new patient inquiries to physicians

CRH Medical Corporation announced today that its innovative marketing program is providing significant new patient inquiries to physicians listed on the Company's website who have been trained in the use of the Company's proprietary technology and methods known as the CRH O'Regan System.

15 Jun 2010

Fluorescent cancerous tumors for early detection

Researchers at the Ecole Polytechnique F-d-rale de Lausanne (EPFL) in Switzerland have established a procedure where cancerous tumors in the bladder become fluorescent and are more easily discoverable under blue light. The Food and Drug Administration (FDA) approved the technique- already in practice in Europe - for the American market. Under the name Cysview-, the product is commercialized by Photocure and GE Healthcare as the most efficient detection technique for early stage bladder cancer.

14 Jun 2010

Telormedix initiates Phase I/II clinical study of TMX-101 for treating NMIBC

Telormedix, a clinical stage biopharmaceutical company focused on targeted immunity in the treatment of cancer and other diseases, today announced the start of a Phase I/II clinical study of TMX-101 for the treatment of Non-Muscle Invasive Bladder Cancer. TMX-101 is an immunotherapeutic compound and Telormedix has already recruited the first patients for this clinical study.

14 Jun 2010

Study finds survival disparities among patients with colorectal cancer

Disparities in cancer stage and treatment are the main reasons why Medicaid-insured and uninsured rectal cancer patients are twice as likely to die within five years as privately insured patients. That is the conclusion of a new study published early online in Cancer, a peer-reviewed journal of the American Cancer Society. Because poorer survival among rectal cancer patients without private insurance is largely attributable to later cancer stage at diagnosis and inadequate treatment, disparities may be lessened through health care reform.

14 Jun 2010

Type 2 diabetes doubles risk of cancer in women

Type 2 adult-onset diabetes causes insulin-like hormones to circulate through the body. A new study finds this has a surprisingly positive effect on reducing the rate of prostate cancer in men, but is bad news for women: Type 2 diabetes may double the risk of female genital and other cancers.

11 Jun 2010

APP Pharmaceuticals to commence marketing of Oxaliplatin Injection in U.S

Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that APP Pharmaceuticals will immediately begin marketing Oxaliplatin Injection (liquid) in the U.S. The U.S. Food and Drug Administration granted approval to market Oxaliplatin Injection in two dosage strengths to Fresenius Kabi Oncology Limited. APP Pharmaceuticals and Fresenius Kabi Oncology Limited are members of the Fresenius Kabi Group of companies. APP currently markets the lyophilized product, Oxaliplatin for Injection, 50 mg and 100 mg.

11 Jun 2010

TF2 bispecific antibody pretargeted therapy prolongs survival in animal model of human colonic cancer

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that pretargeted therapy with TF2, a bispecific antibody against carcinoembryonic antigen (CEA) and a small peptide, delayed tumor growth and prolonged survival in an animal model of human colonic cancer.

10 Jun 2010

Scientists discover how polyphenols present in red wine and green tea inhibit prostate cancer growth

In what could lead to a major advance in the treatment of prostate cancer, scientists now know exactly why polyphenols in red wine and green tea inhibit cancer growth. This new discovery, published online in The FASEB Journal, explains how antioxidants in red wine and green tea produce a combined effect to disrupt an important cell signaling pathway necessary for prostate cancer growth.

10 Jun 2010

Bowel cancer – Second largest cancer killer in Australia

Bowel cancer incidence is rising at an alarming rate all over Australia. A new report shows that the highest number of bowel cancer deaths is concentrated in Brisbane and the Gold Coast.

9 Jun 2010

Myriad Pharmaceuticals announces strategic initiatives to focus on oncology pipeline

Myriad Pharmaceuticals, Inc. today announced several strategic initiatives to focus the Company's efforts on its oncology pipeline and to conserve its financial resources to extend the Company's projected cash runway beyond 2013.

9 Jun 2010

Synta presents positive clinical results from STA-9090 Hsp90 inhibitor trials in solid tumors at ASCO 2010

Synta Pharmaceuticals Corp. announced that clinical results for two Phase 1 trials of STA-9090 in solid tumors, as well as 12 month updated survival results from the SYMMETRY trial of elesclomol in metastatic melanoma, were presented at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO).

8 Jun 2010

Colon Cancer News and Research

Latest Colon Cancer News and Research

Asbestos induces cell necrosis, promotes tumor growth

Tolerx presents preclinical data on TRX518 anti-GITR immunotherapy for cancer

Automated calls can increase colon cancer screening rates by 30%: Study

Scientists report potential toxicity of nanoparticles in consumer products

Shift in balance between good and bad bacteria in gut could be a harbinger of colon cancer: Study

New presentations on neuroendocrine tumors at ESMO 12th World Congress on Gastrointestinal Cancer

Protect Your Lungs, LUNGevity Foundation announce merger

Curis reports topline results from GDC-0449 Phase II clinical trial for metastatic colorectal cancer

Researchers examine rates of cancer in British white and British Indian population

CRH Medical's marketing program provides new patient inquiries to physicians

Fluorescent cancerous tumors for early detection

Telormedix initiates Phase I/II clinical study of TMX-101 for treating NMIBC

Study finds survival disparities among patients with colorectal cancer

Type 2 diabetes doubles risk of cancer in women

APP Pharmaceuticals to commence marketing of Oxaliplatin Injection in U.S

TF2 bispecific antibody pretargeted therapy prolongs survival in animal model of human colonic cancer

Scientists discover how polyphenols present in red wine and green tea inhibit prostate cancer growth

Bowel cancer – Second largest cancer killer in Australia

Myriad Pharmaceuticals announces strategic initiatives to focus on oncology pipeline

Synta presents positive clinical results from STA-9090 Hsp90 inhibitor trials in solid tumors at ASCO 2010

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Colon Cancer News and Research

Latest Colon Cancer News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in